Home Depot Posts Mixed Q4 Earnings, Hikes Dividend By 10%, Forecasts Decline In FY23 EPS

Home improvement retailer Home Depot Inc (NYSE:HD) reported fourth-quarter FY22 sales growth of 0.3% year-on-year to $35.83 billion, marginally missing the consensus…
  • Home improvement retailer Home Depot Inc (NYSE:HD) reported fourth-quarter FY22 sales growth of 0.3% year-on-year to $35.83 billion, marginally missing the consensus of $35.97 billion.
  • Customer transactions for the quarter fell 6%. Comparable sales decreased 0.3%, and comparable sales in the U.S. slipped 0.3%.
  • Gross profit rose 0.5% Y/Y to $11.9 billion. The operating margin was 13.3%, and operating income for the quarter fell 1.5% to $4.75 billion.
  • The operating expenses increased 1.9% Y/Y to $7.2 billion.
  • EPS of $3.30 beat the analyst consensus of $3.28.
  • The average ticket in Q4 was $90.05, a 5.8% growth, and sales per square foot declined 0.1% to $571.15.
  • The company held $2.8 billion in cash and equivalents as of January 29, 2023. Net cash provided by operating activities for the year totaled $14.62 billion.
  • Beginning in Q1 of FY23, Home Depot will invest an additional approximately $1 billion in annualized compensation for frontline, hourly associates.
  • The company’s board of directors approved a 10% increase in its quarterly dividend to $2.09 per share, which equates to an annual dividend of $8.36 per share.
  • The dividend is payable on March 23, 2023, to shareholders of record on the close of business on March 9, 2023.
  • Outlook FY23: Home Depot sees sales growth and comparable sales growth to be approximately flat compared to FY22.
  • HD forecasts EPS-percent -decline to be mid-single digits. The company expects an FY23 operating margin of 14.5%.
  • Price Action: HD shares traded lower by 3.96% at $305.37 in premarket on the last check Tuesday.
Total
0
Shares
Related Posts
Read More

Restaurant Chain Cracker Barrel Posts Mixed Q3 Earnings Due To Lower Traffic: Details

Cracker Barrel Old Country Store reported a 1.9% decline in third-quarter FY24 sales to $817.135 million, missing the $820.614 million estimate. Comparable store retail sales fell 3.8%, with restaurant sales down 1.5%. Despite this, adjusted EPS of $0.88 exceeded the $0.66 estimate. The company revised its FY24 sales outlook to $3.47 billion - $3.51 billion.

CBRL

Read More

Theriva Biologics Announces Presentation At ESMO Congress 2023 Featuring Survival Outcomes In Phase 1 Study Evaluating VCN-01 In Combination With Durvalumab In Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck

-Results from investigator-sponsored study in collaboration with the Institut Catala d'Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1- -Key Opinion Leader

TOVX